Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer

Current Pharmaceutical Design

Volumn 18, Issue 17, 2012, Pages 2395-2403

  Liu, Han ^a   Ma, Qingyong ^a   Xu, Qinhong ^a   Lei, Jianjun ^a   Li, Xuqi ^a   Wang, Zheng ^a   Wu, Erxi ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Desmoplasia; Hypoxia; Pancreatic cancer; Perineural invasion; Therapeutic targets

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CHEMOKINE RECEPTOR CX3CR1; CYCLOOXYGENASE 2; FRACTALKINE; GAMMA SYNUCLEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCOSE TRANSPORTER; HEME OXYGENASE 1; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MYELIN ASSOCIATED GLYCOPROTEIN; NERVE CELL ADHESION MOLECULE; NERVE GROWTH FACTOR; NEUROTROPHIN; PLATELET DERIVED GROWTH FACTOR; POP33 FUSION PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SLT VEGF FUSION PROTEIN; TIRAPAZAMINE; TOP3 FUSION PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANOXIA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CYTOTOXICITY; DESMOPLASIA; DYSPLASIA; EXTRACELLULAR MATRIX; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HYPOXIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOLECULAR PATHOLOGY; NEUROTROPISM; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC STELLATE CELL; PERINEURAL INVASION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; SCHWANN CELL; SPINAL GANGLION; UTERINE CERVIX CANCER;

EID: 84860439526     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128112092395     Document Type: Review

References (117)

1. Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 2006; 24: 87-94.
2. Jemal A, Siegel R, Xu J, Ward E, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 197-209.
4. Cartwright T, Richards DA, Boehm KA. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control 2008; 15: 308-13.
5. Li JH, Ma QY, Liu H, et al. Relationship between Neural Alteration and Perineural Invasion in Pancreatic Cancer Patients with Hyperglycemia. Plos One 2011; 6(2): e17385.
6. Zhang M, Ma Q, Hu H, et al. Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-1alpha under normoxic condition. Cancer Lett 2011; 303: 108-17.
7. Hu HT, Ma QY, Zhang D, et al. HIF-1 alpha links betaadrenoceptor agonists and pancreatic cancer cells under normoxic condition. Acta Pharmacol Sin 2010; 31: 102-10.
8. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007; 6: 1186-97.
9. Pour PM, Bell RH, Batra SK. Neural invasion in the staging of pancreatic cancer. Pancreas 2003; 26: 322-5.
10. Kayahara M, Nagakawa T, Konishi I, Ueno K, Ohta T, Miyazaki I. Clinicopathological study of pancreatic carcinoma with particular reference to the invasion of the extrapancreatic neural plexus. Int J Pancreatol 1991; 10: 105-11.
11. Ceyhan GO, Michalski CW, Demir IE, Muller MW, Friess H. Pancreatic pain. Best Pract Res Clin Gastroenterol 2008; 22: 31-44.
12. Liu B, Lu KY. Neural invasion in pancreatic carcinoma. Hepatobiliary Pancreat Dis Int 2002; 1: 469-76.
13. Nagakawa T, Kayahara M, Ueno K, Ohta T, Konishi I, Miyazaki I. Clinicopathological study on neural invasion to the extrapancreatic nerve plexus in pancreatic cancer. Hepatogastroenterology 1992; 39: 51-5.
14. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer 2009; 115: 3379-91.
15. Ceyhan GO, Giese NA, Erkan M, et al. The neurotrophic factor artemin promotes pancreatic cancer invasion. Annals of Surgery 2006; 244: 274-81.
16. Zhu Z, Friess H, diMola FF, et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 1999; 17: 2419-28.
17. Zhu ZW, Friess H, Wang L, et al. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clinical Cancer Research 2001; 7: 105-12.
18. Dai H, Li R, Wheeler T, et al. Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol 2007; 38: 299-307.
19. Ceyhan GO, Demir IE, Altintas B, et al. Neural invasion in pancreatic cancer: a mutual tropism between neurons and cancer cells. Biochemical and Biophysical Research Communications 2008; 374: 442-7.
20. Kayahara M, Nakagawara H, Kitagawa H, Ohta T. The nature of neural invasion by pancreatic cancer. Pancreas 2007; 35: 218-23.
21. Zhu Z, Kleeff J, Kayed H, et al. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Molecular Carcinogenesis 2002; 35: 138-47.
22. Djakiew D, Pflug BR, Delsite R, et al. Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. Cancer Res 1993; 53: 1416-20.
23. Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA, Ruggeri BA. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int J Cancer 1999; 81: 417-27.
24. Geldof AA, De Kleijn MA, Rao BR, Newling DW. Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells. J Cancer Res Clin Oncol 1997; 123: 107-12.
25. Adriaenssens E, Vanhecke E, Saule P, et al. Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res 2008; 68: 346-51.
26. Desmet CJ, Peeper DS. The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci 2006; 63: 755-9.
27. Papatsoris AG, Liolitsa D, Deliveliotis C. Manipulation of the nerve growth factor network in prostate cancer. Expert Opin Investig Drugs 2007; 16: 303-9.
28. Marchetti D, McQuillan DJ, Spohn WC, Carson DD, Nicolson GL. Neurotrophin stimulation of human melanoma cell invasion: selected enhancement of heparanase activity and heparanase degradation of specific heparan sulfate subpopulations. Cancer Res 1996; 56: 2856-63.
29. Li J, Ma Q, Liu H, et al. Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia. PLoS One 2011; 6: e17385.
30. Okada Y, Eibl G, Guha S, Duffy JP, Reber HA, Hines OJ. Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clin Exp Metastasis 2004; 21: 285-92.
31. Ayala GE, Dai H, Tahir SA, et al. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Research 2006; 66: 5159-64.
32. Okada Y, Takeyama H, Sato M, et al. Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF). Int J Cancer 1999; 81: 67-73.
33. Gil Z, Cavel O, Kelly K, et al. Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J Natl Cancer Inst 2010; 102: 107-18.
34. Okada Y, Eibl G, Duffy JP, Reber HA, Hines OJ. Glial cell-derived neurotrophic factor upregulates the expression and activation of matrix metalloproteinase-9 in human pancreatic cancer. Surgery 2003; 134: 293-9.
35. Ketterer K, Rao S, Friess H, Weiss J, Buchler MW, Korc M. Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin Cancer Res 2003; 9: 5127-36.
36. Kowalski PJ, Paulino AF. Perineural invasion in adenoid cystic carcinoma: Its causation/promotion by brain-derived neurotrophic factor. Hum Pathol 2002; 33: 933-6.
37. Kameda K, Shimada H, Ishikawa T, et al. Expression of highly polysialylated neural cell adhesion molecule in pancreatic cancer neural invasive lesion. Cancer Lett 1999; 137: 201-7.
38. Seki H, Tanaka J, Sato Y, Kato Y, Umezawa A, Koyama K. Neural cell adhesion molecule (NCAM) and perineural invasion in bile duct cancer. J Surg Oncol 1993; 53: 78-83.
39. Schreiber SC, Giehl K, Kastilan C, et al. Polysialylated NCAM represses E-cadherin-mediated cell-cell adhesion in pancreatic tumor cells. Gastroenterology 2008; 134: 1555-66.
40. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGFreceptor signalling. Nat Cell Biol 2001; 3: 650-7.
41. Swanson BJ, McDermott KM, Singh PK, Eggers JP, Crocker PR, Hollingsworth MA. MUC1 is a counter-receptor for myelinassociated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Research 2007; 67: 10222-9.
42. Anderson TD, Feldman M, Weber RS, Ziober AF, Ziober BL. Tumor deposition of laminin-5 and the relationship with perineural invasion. Laryngoscope 2001; 111: 2140-3.
43. Marchesi F, Piemonti L, Fedele G, et al. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res 2008; 68: 9060-9.
44. Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9: 917-24.
45. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-4.
46. Pan Y, Lloyd C, Zhou H, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997; 387: 611-7.
47. Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci 2004; 20: 1150-60.
48. Marchesi F, Locatelli M, Solinas G, Erreni M, Allavena P, Mantovani A. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J Neuroimmunol 2010; 224: 39-44.
49. Hibi T, Mori T, Fukuma M, et al. Synuclein-gamma Is Closely Involved in Perineural Invasion and Distant Metastasis in Mouse Models and Is a Novel Prognostic Factor in Pancreatic Cancer. Clinical Cancer Research 2009; 15: 2864-71.
50. Li DD, Guo JF, Huang JJ, et al. Rhabdastrellic Acid-A Induced Autophagy-Associated Cell Death through Blocking Akt Pathway in Human Cancer Cells. Plos One 2010; 5: -.
51. Wang F, Li SS, Segersvard R, et al. Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis. Am J Pathol 2007; 170: 469-77.
52. Couvelard A, O'Toole D, Turley H, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005; 92: 94-101.
53. Li XQ, Zhang LJ, Meshinchi S, et al. Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. Diabetes 2006; 55: 2965-73.
54. Konstantinova I, Lammert E. Microvascular development: learning from pancreatic islets. Bioessays 2004; 26: 1069-75.
55. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003; 22: 3213-20.
56. Le QTX, Moon J, Redman M, et al. Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222. J Clin Oncol 2009; 27: 3014-9.
57. Zhang J, Cao J, Weng QJ, et al. Suppression of Hypoxia-Inducible Factor 1 alpha (HIF-1 alpha) by Tirapazamine Is Dependent on eIF2 alpha Phosphorylation Rather Than the mTORC1/4E-BP1 Pathway. Plos One 2010; 5: -.
58. Koh MY, Spivak-Kroizman T, Venturini S, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 alpha. Mol Cancer Ther 2008; 7: 90-100.
59. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1 alpha. Mol Cancer Ther 2004; 3: 233-44.
60. Jacoby JJ, Erez B, Korshunova MV, et al. Treatment with HIF-1 alpha Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice. J Thorac Oncol 2010; 5: 940-9.
61. Palayoor ST, Mitchell JB, Cerna D, DeGraff W, John-Aryankalayil M, Coleman CN. PX-478, an inhibitor of hypoxia-inducible factor- 1 alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 2008; 123: 2430-7.
62. Schwartz DL, Powis G, Thitai-Kumar A, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009; 8: 947-58.
63. Kizaka-Kondoh S, Itasaka S, Zeng LH, et al. Selective Killing of Hypoxia-Inducible Factor-1-Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer. Clin Cancer Res 2009; 15: 3433-41.
64. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: A target for selective cancer therapy. Cancer Sci 2003; 94: 1021-8.
65. Harada H, Hiraoka M, Kizaka-Kondoh S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 2002; 62: 2013-8.
66. Backer MV, Backer JM. Targeting endothelial cells overexpressing VEGFR-2: Selective toxicity of Shiga-like toxin-VEGF fusion proteins. Bioconjugate Chem 2001; 12: 1066-73.
67. Backer MV, Gaynutdinov TI, Patel V, et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 2005; 4: 1423-9.
68. Hotz B, Backer MV, Backer JM, Buhr HJ, Hotz HG. Specific Targeting of Tumor Endothelial Cells by a Shiga-like Toxin- Vascular Endothelial Growth Factor Fusion Protein as a Novel Treatment Strategy for Pancreatic Cancer. Neoplasia 2010; 12: 797-U148.
69. Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer - Role of pancreatic stellate cells. Pancreas 2004; 29: 179-87.
70. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63: 2649-57.
71. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: Basic and clinical aspects. Gastroenterology 2005; 128: 1606-25.
72. Vonlaufen A, Phillips PA, Xu ZH, e al. Pancreatic stellate cells and pancreatic cancer cells: An unholy alliance. Cancer Res 2008; 68: 7707-10.
73. Yen TNF, Aardal NP, Bronner MP, et al. Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery 2002; 131: 129-34.
74. Menke A, Adler G. TGF beta-induced fibrogenesis of the pancreas. Int J Gastro Cancer 2002; 31: 41-6.
75. Apte MV, Wilson JS. Mechanisms of pancreatic fibrosis. Digest Dis 2004; 22: 273-9.
76. Armstrong T, Packham G, Murphy LB, et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10: 7427-37.
77. Binkley CE, Zhang LZ, Greenson JK, et al. The molecular basis of pancreatic fibrosis - Common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas 2004; 29: 254-63.
78. Koninger J, Giese T, di Mola FF, et al. Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Bioph Res Co 2004; 322: 943-9.
79. Yoshida S, Yokota T, Ujiki M, et al. Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through the MAP kinase pathway. Biochem Bioph Res Co 2004; 323: 1241-5.
80. Bachem MG, Schunemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005; 128: 907-21.
81. Apte MV, Wilson JS. Stellate cell activation in alcoholic pancreatitis. Pancreas 2003; 27: 316-20.
82. Apte MV, Haber PS, Darby SJ, et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut 1999; 44: 534-41.
83. Luttenberger T, Schmid-Kotsas A, Menke A, et al. Platelet-derived growth factors stimulate proliferation and extracellular matrix synthesis of pancreatic stellate cells: Implications in pathogenesis of pancreas fibrosis. Lab Invest 2000; 80: 47-55.
84. Schneider E, Schmid-Kotsas A, Zhao JS, et al. Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells. Am J Physiol-Cell Ph 2001; 281: C532-C43.
85. Shek FWT, Benyon RC, Walker FM, et al. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am J Pathol 2002; 160: 1787-98.
86. Mews P, Phillips P, Fahmy R, et al. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut 2002; 50: 535-41.
87. Phillips PA, Wu MJ, Kumar RK, et al. Cell migration: a novel aspect of pancreatic stellate cell biology. Gut 2003; 52: 677-82.
88. Hama K, Ohnishi H, Aoki H, e al. Angiotensin II promotes the proliferation of activated pancreatic stellate cells by Smad7 induction through a protein kinase C pathway. Biochem Bioph Res Co 2006; 340: 742-50.
89. Gao RP, Brigstock DR. Connective tissue growth factor (CCN2) in rat pancreatic stellate cell function: Integrin zeta(5)beta(1) as a novel CCN2 receptor. Gastroenterology 2005; 129: 1019-30.
90. Aoki H, Ohnishi H, Hama K, et al. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. Am J Physiol-Cell Ph 2007; 292: C259-C68.
91. Ohnishi N, Miyata T, Ohnishi H, et al. Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis. Gut 2003; 52: 1487-93.
92. Masamune A, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Endothelin-1 stimulates contraction and migration of rat pancreatic stellate cells. World J Gastroenterol 2005; 11: 6144-51.
93. Jaster R, Hilgendorf I, Fitzner B, e al. Regulation of pancreatic stellate cell function in vitro: biological and molecular effects of all-trans retinoic acid. Biochem Pharmacol 2003; 66: 633-41.
94. Won JH, Zhang Y, Ji BA, Logsdon CD, Yule DI. Phenotypic changes in mouse pancreatic stellate cell Ca2+ signaling events following activation in culture and in a disease model of pancreatitis. Mol Biol Cell 2011; 22: 421-36.
95. Apte MV, Pirola RC, Wilson JS. Battle-scarred pancreas: Role of alcohol and pancreatic stellate cells in pancreatic fibrosis. J Gastroen Hepatol 2006; 21: S97-S101.
96. Masamune A, Satoh A, Watanabe T, et al. Effects of Ethanol and Its Metabolites on Human Pancreatic Stellate Cells. Digest Dis Sci 2010; 55: 204-11.
97. Schwer CI, Mutschler M, Stoll P, et al. Carbon monoxide releasing molecule-2 inhibits pancreatic stellate cell proliferation by activating p38 mitogen-activated protein kinase/heme oxygenase-1 signaling. Mol Pharmacol 2010; 77: 660-9.
98. Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2008; 295: G709-17.
99. Masamune A, Kikuta K, Watanabe T, et al. Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut 2009; 58: 550-9.
100. Haber PS, Keogh GW, Apte MV, et al. Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. Am J Pathol 1999; 155: 1087-95.
101. Kuno A, Yamada T, Masuda K, et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 2003; 124: 1010-9.
102. Ohnishi H, Miyata T, Yasuda H, et al. Distinct roles of Smad2-, Smad3-, and ERK-dependent pathways in transforming growth factor-beta1 regulation of pancreatic stellate cellular functions. J Biol Chem 2004; 279: 8873-8.
103. Kikuta K, Masamune A, Satoh M, Suzuki N, Satoh K, Shimosegawa T. Hydrogen peroxide activates activator protein-1 and mitogen-activated protein kinases in pancreatic stellate cells. Mol Cell Biochem 2006; 291: 11-20.
104. Masamune A, Kikuta K, Suzuki N, Satoh M, Satoh K, Shimosegawa T. A c-Jun NH2-terminal kinase inhibitor SP600125 (anthra[1,9-cd]pyrazole-6 (2H)-one) blocks activation of pancreatic stellate cells. J Pharmacol Exp Ther 2004; 310: 520-7.
105. Masamune A, Kikuta K, Satoh M, Suzuki N, Shimosegawa T. Protease-activated receptor-2-mediated proliferation and collagen production of rat pancreatic stellate cells. J Pharmacol Exp Ther 2005; 312: 651-8.
106. Yamada T, Kuno A, Ogawa K, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. J Pharmacol Exp Ther 2005; 313: 36-45.
107. Masamune A, Kikuta K, Satoh M, Satoh A, Shimosegawa T. Alcohol activates activator protein-1 and mitogen-activated protein kinases in rat pancreatic stellate cells. J Pharmacol Exp Ther 2002; 302: 36-42.
108. Jaster R, Sparmann G, Emmrich J, Liebe S. Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells. Gut 2002; 51: 579-84.
109. McCarroll JA, Phillips PA, Kumar RK, et al. Pancreatic stellate cell migration: role of the phosphatidylinositol 3-kinase(PI3- kinase) pathway. Biochem Pharmacol 2004; 67: 1215-25.
110. Masamune A, Kikuta K, Satoh M, Sakai Y, Satoh A, Shimosegawa T. Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells. J Biol Chem 2002; 277: 141-7.
111. Yoshida S, Ujiki M, Ding XZ, et al. Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol Cancer 2005; 4: 27.
112. McCarroll JA, Phillips PA, Santucci N, Pirola RC, Wilson JS, Apte MV. Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis. Gut 2006; 55: 79-89.
113. Dornhofer N, Spong S, Bennewith K, et al. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2006; 66: 5816-27.
114. Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 2006; 5: 1108-16.
115. Yoo BM, Yeo M, Oh TY, et al. Amelioration of pancreatic fibrosis in mice with defective TGF-beta signaling. Pancreas 2005; 30: e71-9.
116. Bachem MG, Zhou S, Buck K, Schneiderhan W, Siech M. Pancreatic stellate cells--role in pancreas cancer. Langenbecks Arch Surg 2008; 393: 891-900.
117. Zhang W, Erkan M, Abiatari I, et al. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biol Ther 2007; 6: 218-27.